<?xml version='1.0' encoding='utf-8'?>
<document id="26051874"><sentence text="Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers."><entity charOffset="20-33" id="DDI-PubMed.26051874.s1.e0" text="Empagliflozin" /><entity charOffset="38-50" id="DDI-PubMed.26051874.s1.e1" text="Pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s1.e0" e2="DDI-PubMed.26051874.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s1.e0" e2="DDI-PubMed.26051874.s1.e1" /></sentence><sentence text="The aim was to investigate the effects of coadministration of the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin with the thiazolidinedione pioglitazone"><entity charOffset="66-80" id="DDI-PubMed.26051874.s2.e0" text="sodium glucose" /><entity charOffset="115-128" id="DDI-PubMed.26051874.s2.e1" text="empagliflozin" /><entity charOffset="138-168" id="DDI-PubMed.26051874.s2.e2" text="thiazolidinedione pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s2.e0" e2="DDI-PubMed.26051874.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s2.e0" e2="DDI-PubMed.26051874.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s2.e0" e2="DDI-PubMed.26051874.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s2.e1" e2="DDI-PubMed.26051874.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s2.e1" e2="DDI-PubMed.26051874.s2.e2" /></sentence><sentence text="" /><sentence text="In study 1, 20 healthy volunteers received 50 mg of empagliflozin alone for 5 days, followed by 50 mg of empagliflozin coadministered with 45 mg of pioglitazone for 7 days and 45 mg of pioglitazone alone for 7 days in 1 of 2 treatment sequences"><entity charOffset="52-65" id="DDI-PubMed.26051874.s4.e0" text="empagliflozin" /><entity charOffset="105-118" id="DDI-PubMed.26051874.s4.e1" text="empagliflozin" /><entity charOffset="148-160" id="DDI-PubMed.26051874.s4.e2" text="pioglitazone" /><entity charOffset="185-197" id="DDI-PubMed.26051874.s4.e3" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e0" e2="DDI-PubMed.26051874.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e0" e2="DDI-PubMed.26051874.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e0" e2="DDI-PubMed.26051874.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e0" e2="DDI-PubMed.26051874.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e1" e2="DDI-PubMed.26051874.s4.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e1" e2="DDI-PubMed.26051874.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e1" e2="DDI-PubMed.26051874.s4.e3" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e2" e2="DDI-PubMed.26051874.s4.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s4.e2" e2="DDI-PubMed.26051874.s4.e3" /></sentence><sentence text=" In study 2, 20 volunteers received 45 mg of pioglitazone alone for 7 days and 10, 25, and 50 mg of empagliflozin for 9 days coadministered with 45 mg of pioglitazone for the first 7 days in 1 of 4 treatment sequences"><entity charOffset="45-57" id="DDI-PubMed.26051874.s5.e0" text="pioglitazone" /><entity charOffset="100-113" id="DDI-PubMed.26051874.s5.e1" text="empagliflozin" /><entity charOffset="154-166" id="DDI-PubMed.26051874.s5.e2" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s5.e0" e2="DDI-PubMed.26051874.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s5.e0" e2="DDI-PubMed.26051874.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s5.e0" e2="DDI-PubMed.26051874.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s5.e1" e2="DDI-PubMed.26051874.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s5.e1" e2="DDI-PubMed.26051874.s5.e2" /></sentence><sentence text="" /><sentence text="Pioglitazone exposure (Cmax and AUC) increased when coadministered with empagliflozin versus monotherapy in study 1"><entity charOffset="0-12" id="DDI-PubMed.26051874.s7.e0" text="Pioglitazone" /></sentence><sentence text=" The geometric mean ratio (GMR) for pioglitazone Cmax at steady state (Cmax,ss) and for AUC during the dosing interval at steady state (AUCτ,ss) when coadministered with empagliflozin versus administration alone was 187"><entity charOffset="36-48" id="DDI-PubMed.26051874.s8.e0" text="pioglitazone" /></sentence><sentence text="89% (95% CI, 166" /><sentence text="35%-212" /><sentence text="23%) and 157" /><sentence text="97% (95% CI, 148" /><sentence text="02%-168" /><sentence text="58%), respectively" /><sentence text=" Because an increase in pioglitazone exposure was not expected, based on in vitro data, a second study was conducted with the empagliflozin doses tested in Phase III trials"><entity charOffset="24-36" id="DDI-PubMed.26051874.s15.e0" text="pioglitazone" /><entity charOffset="126-139" id="DDI-PubMed.26051874.s15.e1" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.26051874.s15.e0" e2="DDI-PubMed.26051874.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s15.e0" e2="DDI-PubMed.26051874.s15.e1" /></sentence><sentence text=" In study 2, pioglitazone exposure decreased marginally when coadministered with empagliflozin"><entity charOffset="81-94" id="DDI-PubMed.26051874.s16.e0" text="empagliflozin" /></sentence><sentence text=" The GMR for pioglitazone Cmax,ss when coadministered with empagliflozin versus administration alone was 87"><entity charOffset="13-25" id="DDI-PubMed.26051874.s17.e0" text="pioglitazone" /><entity charOffset="59-72" id="DDI-PubMed.26051874.s17.e1" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.26051874.s17.e0" e2="DDI-PubMed.26051874.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s17.e0" e2="DDI-PubMed.26051874.s17.e1" /></sentence><sentence text="74% (95% CI, 73" /><sentence text="88%-104" /><sentence text="21%) with empagliflozin 10 mg, 90"><entity charOffset="10-23" id="DDI-PubMed.26051874.s20.e0" text="empagliflozin" /></sentence><sentence text="23% (95% CI, 66" /><sentence text="84%-121" /><sentence text="82%) with empagliflozin 25 mg, and 89"><entity charOffset="10-23" id="DDI-PubMed.26051874.s23.e0" text="empagliflozin" /></sentence><sentence text="85% (95% CI, 71"><entity charOffset="9-11" id="DDI-PubMed.26051874.s24.e0" text="CI" /></sentence><sentence text="03%-113" /><sentence text="66%) with empagliflozin 50 mg"><entity charOffset="10-23" id="DDI-PubMed.26051874.s26.e0" text="empagliflozin" /></sentence><sentence text=" The GMR for pioglitazone AUCτ,ss when coadministered with empagliflozin versus administration alone was 90"><entity charOffset="13-30" id="DDI-PubMed.26051874.s27.e0" text="pioglitazone AUCτ" /><entity charOffset="59-72" id="DDI-PubMed.26051874.s27.e1" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.26051874.s27.e0" e2="DDI-PubMed.26051874.s27.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s27.e0" e2="DDI-PubMed.26051874.s27.e1" /></sentence><sentence text="01% (95% CI, 77"><entity charOffset="9-21" id="DDI-PubMed.26051874.s28.e0" text="CI" /></sentence><sentence text="91%-103" /><sentence text="99%) with empagliflozin 10 mg, 88"><entity charOffset="10-23" id="DDI-PubMed.26051874.s30.e0" text="empagliflozin" /></sentence><sentence text="98% (95% CI, 72"><entity charOffset="9-11" id="DDI-PubMed.26051874.s31.e0" text="CI" /></sentence><sentence text="69%-108" /><sentence text="92%) with empagliflozin 25 mg, and 91"><entity charOffset="10-23" id="DDI-PubMed.26051874.s33.e0" text="empagliflozin" /></sentence><sentence text="10% (95% CI, 77"><entity charOffset="9-21" id="DDI-PubMed.26051874.s34.e0" text="CI" /></sentence><sentence text="40%-107" /><sentence text="22%) with empagliflozin 50 mg"><entity charOffset="10-23" id="DDI-PubMed.26051874.s36.e0" text="empagliflozin" /></sentence><sentence text=" The effects of empagliflozin on pioglitazone exposure are not considered to be clinically relevant"><entity charOffset="16-29" id="DDI-PubMed.26051874.s37.e0" text="empagliflozin" /><entity charOffset="33-45" id="DDI-PubMed.26051874.s37.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s37.e0" e2="DDI-PubMed.26051874.s37.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s37.e0" e2="DDI-PubMed.26051874.s37.e1" /></sentence><sentence text=" Empagliflozin exposure was unaffected by coadministration with pioglitazone"><entity charOffset="1-14" id="DDI-PubMed.26051874.s38.e0" text="Empagliflozin" /><entity charOffset="64-76" id="DDI-PubMed.26051874.s38.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s38.e0" e2="DDI-PubMed.26051874.s38.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s38.e0" e2="DDI-PubMed.26051874.s38.e1" /></sentence><sentence text=" Empagliflozin and pioglitazone were well tolerated when administered alone or in combination"><entity charOffset="1-14" id="DDI-PubMed.26051874.s39.e0" text="Empagliflozin" /><entity charOffset="19-31" id="DDI-PubMed.26051874.s39.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s39.e0" e2="DDI-PubMed.26051874.s39.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s39.e0" e2="DDI-PubMed.26051874.s39.e1" /></sentence><sentence text=" In study 1, adverse events were reported in 1 of 19 participants on empagliflozin 50 mg alone, 4 of 20 on pioglitazone alone, and 5 of 18 on combination treatment"><entity charOffset="69-82" id="DDI-PubMed.26051874.s40.e0" text="empagliflozin" /><entity charOffset="107-119" id="DDI-PubMed.26051874.s40.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.26051874.s40.e0" e2="DDI-PubMed.26051874.s40.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s40.e0" e2="DDI-PubMed.26051874.s40.e1" /></sentence><sentence text=" In study 2, adverse events were reported in 8 of 20 participants on pioglitazone alone, 10 of 18 when coadministered with empagliflozin 10 mg, 5 of 17 when coadministered with empagliflozin 25 mg, and 6 of 16 when coadministered with empagliflozin 50 mg"><entity charOffset="69-81" id="DDI-PubMed.26051874.s41.e0" text="pioglitazone" /><entity charOffset="123-136" id="DDI-PubMed.26051874.s41.e1" text="empagliflozin" /><entity charOffset="177-190" id="DDI-PubMed.26051874.s41.e2" text="empagliflozin" /><entity charOffset="235-248" id="DDI-PubMed.26051874.s41.e3" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e0" e2="DDI-PubMed.26051874.s41.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e0" e2="DDI-PubMed.26051874.s41.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e0" e2="DDI-PubMed.26051874.s41.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e0" e2="DDI-PubMed.26051874.s41.e3" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e1" e2="DDI-PubMed.26051874.s41.e1" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e1" e2="DDI-PubMed.26051874.s41.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e1" e2="DDI-PubMed.26051874.s41.e3" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e2" e2="DDI-PubMed.26051874.s41.e2" /><pair ddi="false" e1="DDI-PubMed.26051874.s41.e2" e2="DDI-PubMed.26051874.s41.e3" /></sentence><sentence text="" /><sentence text="These results indicate that pioglitazone and empagliflozin can be coadministered without dose adjustments"><entity charOffset="28-40" id="DDI-PubMed.26051874.s43.e0" text="pioglitazone" /><entity charOffset="45-58" id="DDI-PubMed.26051874.s43.e1" text="empagliflozin" /><pair ddi="false" e1="DDI-PubMed.26051874.s43.e0" e2="DDI-PubMed.26051874.s43.e0" /><pair ddi="false" e1="DDI-PubMed.26051874.s43.e0" e2="DDI-PubMed.26051874.s43.e1" /></sentence><sentence text=" EudraCT identifiers: 2008-006087-11 (study 1) and 2009-018089-36 (study 2)" /><sentence text="" /></document>